Approximately 47 million people have dementia worldwide, with this figure, it is expected to almost triple by 2050. Most people with dementia (approximately twothirds) live in low-and middle-income countries (LMICs). This presents a significant challenge for such countries that often have limited financial resources and less well-developed health and social care systems. In the absence of a cure, reducing the future costs of dementia care and burden of disease may be best achieved by a greater emphasis on (1) more timely diagnosis with earlier intervention to maintain functional independence and (2) undertaking "screening" in groups at high risk of developing dementia, case finding, and using brief cognitive assessment instruments.
| INTRODUCTION
Dementia is a syndrome characterized by progressive decline in cognitive (eg, memory, language, orientation, and judgement) and physical functioning resulting in loss of independence.
1 Approximately 47 million people have dementia worldwide; with this figure, it is expected to almost triple by 2050. In 2015, the cost of dementia was estimated at 818 billion dollars, and by 2030, the cost is expected to exceed one trillion dollars. 2 Most people with dementia (approximately two-thirds) live in low-and middle-income countries (LMICs). 2 This presents a significant challenge for such countries which often have limited financial resources, and less well developed health and social care systems. 2 In the absence of a cure, reducing the future costs of dementia care and burden of disease may be best achieved by a greater emphasis on (1) more timely diagnosis with earlier intervention to maintain functional independence and (2) undertaking "screening" in groups at high risk of developing dementia, case finding, using brief cognitive assessment instruments. 3, 4 Population screening for dementia is not currently considered cost-effective; however, case finding has been introduced in some countries, for example, England, with limited success. 3, 4 In clinical settings, a wide range of instruments for dementia screening and diagnosis are currently available [5] [6] [7] [8] ; these can be classified into the following:
(1) Cognitive tests and neuropsychological assessment batteries such as the Mini Mental State Examination (MMSE) or the Addenbrooke's Cognitive Examination. 5, 6 (2) Automated cognitive measures that comprise computerized versions of traditional or newly developed tests. 7, 8 (3) Functional scales assessing core activities of daily living (ADL), eg, bathing dressing and broader instrumental activities of daily living (IADL), eg, managing finances and medication adherence. 9 Notwithstanding, there is currently much variation amongst such assessment instruments due to their psychometric properties (ie, some being more sensitive in identifying different subtypes of dementia), utility (ie, due to expertise needed and time to administer), and discriminative accuracy. 5, 6 Consequently, current evidence and clinical guidance in the UK and other high income countries (HICs) state there is no one tool or approach better than any other and thus recommend a broad range of tests for use in practice depending on the skills of the assessor and the clinical setting. 1, 10 While this can be viewed as positive as it provides a range of choice for clinicians, it can also create difficulties such as diagnostic differences depending on the instrument used and difficulties in cross study comparisons. 5, 6 Regarding current practice in LMICs, cognitive assessment instru- 28 Thailand, 27 and Lebanon especially on items assessing drawing and praxis. 26 To overcome bias due to education and literacy, in some instances, and mainly in the MMSE, education and literacy sensitive items have been adapted, simplified, or omitted including (1) Key points
• Approximately two-thirds of people with dementia live in low and middle income countries (LMICs); this presents a significant challenge for these countries due to limited financial resources, staff training, and health/ social care services.
• Few cognitive assessment and dementia screening tools have been developed specifically for clinical use within LMIC settings.
• Screening for dementia and cognitive impairment in LMICs largely relies on tools adapted from high income countries (HICs); these often lack validation in these settings leading to education, literacy, and cultural biases.
• Research is urgently needed to develop cognitive assessment tools and dementia diagnostic approaches that are appropriate and feasible for clinical use in LMIC settings.
Translations and subsequent cross-cultural adaptations are not always clearly reported, and there are no evidence-based recommendations on how to proceed with adapting specific cognitive tests across different settings. 36 It has been also reported that in addressing linguistic or cultural concerns, original versions may become over simplified or substantially changed, potentially resulting in problems of equivalence. 30 Further, translations and cultural adaptations do not guarantee the psychometric validity of a measure. Therefore, tools adapted from HICs need to be piloted and validated in cognitively healthy and impaired populations using a diagnostic reference to ensure adequate validation in LMIC settings. 13 LMICs to administer and score tests for dementia assessment and diagnosis, methods that are simple, digital (ie, via mobile phone or tablet) and can be administered by the individual themselves or a non-specialist to accurately detect dementia may be of particular importance.
| INSTRUMENTS TO ASSESS COGNITION DEVELOPED SPECIFICALLY FOR LMICS

